Hormone refractory prostate cancer
Information
- Disease name
- Hormone refractory prostate cancer
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00069745 | Completed | Phase 3 | Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen | September 2003 | March 2007 |
| NCT00407251 | Completed | Phase 2 | Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy | February 2007 | |
| NCT00477529 | Completed | Phase 1/Phase 2 | ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer | April 1, 2007 | June 2, 2011 |
| NCT00510718 | Completed | Phase 1 | A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | July 23, 2007 | April 2, 2018 |
| NCT00571675 | Completed | Phase 2 | A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) | October 2007 | September 2010 |
| NCT00583024 | Completed | Phase 2 | Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer | December 2007 | January 31, 2023 |
| NCT00629525 | Completed | Phase 2 | RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer | August 2005 | January 2010 |
| NCT00667199 | Completed | Phase 2 | BAY88-8223, Does Response Study in HRPC Patients | May 30, 2005 | October 6, 2009 |
| NCT00699751 | Completed | Phase 3 | A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases | June 2008 | February 2014 |
| NCT00928252 | Completed | Phase 1/Phase 2 | Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer | June 2009 | June 2016 |
| NCT00987753 | Completed | Phase 1/Phase 2 | Study Evaluating the Safety and Tolerability of L-377202 | March 1999 | November 2001 |
| NCT01215799 | Completed | Phase 2 | Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer | August 2010 | December 2011 |
| NCT01260688 | Completed | Phase 2 | Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel | October 2010 | February 2014 |
| NCT01487863 | Completed | Phase 2 | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | December 2011 | June 2016 |
| NCT01518283 | Completed | Phase 2 | Study of Weekly Cabazitaxel for Advanced Prostate Cancer | May 2012 | July 2016 |
| NCT01741116 | Completed | Phase 2 | Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer | November 2012 | October 2016 |
| NCT00156884 | Completed | Phase 2 | A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer | August 2003 | May 2008 |
| NCT00286091 | Completed | Phase 3 | Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer | January 24, 2006 | April 9, 2014 |
| NCT00286806 | Completed | Phase 1/Phase 2 | A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer | December 2005 | June 2007 |
| NCT02955082 | Recruiting | Phase 2 | The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment | May 25, 2017 | September 30, 2024 |
| NCT00493766 | Terminated | Phase 1 | Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone | May 2006 | |
| NCT00906243 | Terminated | Phase 1/Phase 2 | RNActive®-Derived Therapeutic Vaccine | May 2009 | December 2010 |
| NCT00525408 | Terminated | Phase 2 | A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer | November 2007 | January 2013 |
| NCT01083615 | Terminated | Phase 3 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | March 2010 | March 2013 |
| NCT01194960 | Terminated | Phase 2 | TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) | August 2010 | March 2013 |
| NCT00313482 | Terminated | Phase 2 | PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC | April 2006 | August 2008 |
| NCT00448734 | Unknown status | Phase 1/Phase 2 | A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer | June 2006 | July 2010 |
| NCT02208583 | Unknown status | N/A | Molecular Phenotype Changes and Personalized Treatment for CRPC | June 2014 | December 2016 |
| NCT02691975 | Unknown status | Phase 1/Phase 2 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | April 12, 2016 | June 1, 2021 |
| NCT00795171 | Unknown status | Phase 2 | Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer | November 2008 | July 2011 |
| NCT00411853 | Unknown status | Phase 2 | Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients | June 2007 | June 2012 |
| NCT00133900 | Unknown status | Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy | December 2004 | February 2009 | |
| NCT01590498 | Unknown status | Radiotherapy vs Observation for CRPC | May 2012 | March 2017 | |
| NCT02867345 | Withdrawn | PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer | November 2016 | December 2020 |